The past quarter has brought favorable news for
Genmab, including robust Q1 2025 earnings that outscored EPS expectations but fell short on revenues. Despite a
7.8% drop, analysts have deemed the company among the best healthcare stocks to buy. Institutional owners might take significant action due to Genmab's one-year losses. However, amid patent expiration concerns, the company's strong performance remains undervalued with tremendous growth potential. The company commenced a
share buy-back program in early May 2025, further signaling confidence in its stock prices. Genmab reported strong Q1 2025 revenues and significant DARZALEX sales amounting to US$3 billion. With the company granting
restricted stock units to management and employees, it remains cash-rich and attractive for investors. While concerns around J&J's failure to exercise the option on HexaBody-CD38 arose, Deutsche Bank and analysts like H.C. Wainwright maintain a 'Buy' rating on Genmab. The company's share capital reduction and strong DARZALEX sales point to a promising future. But questions around Genmab's post-Darzalex challenge and trade secret claims by AbbVie weigh on the outlook.
Genmab Stocks News Analytics from Tue, 20 Aug 2024 07:00:00 GMT to Sat, 10 May 2025 07:44:19 GMT -
Rating 7
- Innovation 4
- Information 8
- Rumor -3
